Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Brief Report on the Use of Radiolabeled Somatostatin Analogs for the Diagnosis and Treatment of Metastatic Small-Cell Lung Cancer Patients

Brief Report on the Use of Radiolabeled Somatostatin Analogs for the Diagnosis and Treatment of... BRIEF REPORT Brief Report on the Use of Radiolabeled Somatostatin  Analogs for the Diagnosis and Treatment of Metastatic  Small-Cell Lung Cancer Patients Martina Sollini, MD,* Daniela Farioli, MS,* Armando Froio, MS,* Antonio Chella, MD,† Mattia Asti, PhD,* Roberto Boni, MD,‡ Elisa Grassi, MS,§ Massimo Roncali, MD,* Annibale Versari, MD,* and Paola Anna Erba MD,‡* Key Words: Small-cell lung cancer, Radiolabeled somatosta- Introduction: The demonstration of type 2 somatostatin receptors tin analogs PET/CT, Peptide radioreceptor radionuclide therapy, (SSTRs) in small-cell lung cancer (SCLC) represents the rationale Somatostatin receptors. for the use of positron emission tomography/computed tomography (PET/CT) to determine SSTR expression, and select patients suitable (J Thorac Oncol. 2013;8: 1095-1101) for peptide radioreceptor radionuclide therapy (PRRT) in extensive- disease stage (ED) SCLC. Methods: We evaluated 24 ED-SCLC patients with radiolabeled mall-cell lung cancer (SCLC) accounts for 15% to 18% of SST-analog PET/CT. Lesions at PET/CT scan were semiquantita- Slung cancer. The presence of metastases at diagnosis is asso- tively scored (from 0 to 3+) and compared with contrast-enhanced ciated with a worse prognosis (median survival of 10 months, CT findings. Patients scored as 3+ were admitted to PRRT after 2-year survival rate of 10%). Diagnostic workup of SCLC dosimetric evaluation. Average injected activity/cycle was 2.6 GBq included chest and abdomen computed tomography (CT), brain 90 177 ( http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Brief Report on the Use of Radiolabeled Somatostatin Analogs for the Diagnosis and Treatment of Metastatic Small-Cell Lung Cancer Patients

Erba, Paola Anna
Journal of Thoracic Oncology , Volume 8 (8) – Aug 1, 2013
Download PDF
7 pages

Loading next page...
 
/lp/wolters-kluwer-health/brief-report-on-the-use-of-radiolabeled-somatostatin-analogs-for-the-wq8EWCtqNi

References (19)

Copyright
Copyright © 2013 by the International Association for the Study of Lung Cancer
ISSN
1556-0864
DOI
10.1097/JTO.0b013e318293f051
pmid
23857400
Publisher site
See Article on Publisher Site

Abstract

BRIEF REPORT Brief Report on the Use of Radiolabeled Somatostatin  Analogs for the Diagnosis and Treatment of Metastatic  Small-Cell Lung Cancer Patients Martina Sollini, MD,* Daniela Farioli, MS,* Armando Froio, MS,* Antonio Chella, MD,† Mattia Asti, PhD,* Roberto Boni, MD,‡ Elisa Grassi, MS,§ Massimo Roncali, MD,* Annibale Versari, MD,* and Paola Anna Erba MD,‡* Key Words: Small-cell lung cancer, Radiolabeled somatosta- Introduction: The demonstration of type 2 somatostatin receptors tin analogs PET/CT, Peptide radioreceptor radionuclide therapy, (SSTRs) in small-cell lung cancer (SCLC) represents the rationale Somatostatin receptors. for the use of positron emission tomography/computed tomography (PET/CT) to determine SSTR expression, and select patients suitable (J Thorac Oncol. 2013;8: 1095-1101) for peptide radioreceptor radionuclide therapy (PRRT) in extensive- disease stage (ED) SCLC. Methods: We evaluated 24 ED-SCLC patients with radiolabeled mall-cell lung cancer (SCLC) accounts for 15% to 18% of SST-analog PET/CT. Lesions at PET/CT scan were semiquantita- Slung cancer. The presence of metastases at diagnosis is asso- tively scored (from 0 to 3+) and compared with contrast-enhanced ciated with a worse prognosis (median survival of 10 months, CT findings. Patients scored as 3+ were admitted to PRRT after 2-year survival rate of 10%). Diagnostic workup of SCLC dosimetric evaluation. Average injected activity/cycle was 2.6 GBq included chest and abdomen computed tomography (CT), brain 90 177 (

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Aug 1, 2013

There are no references for this article.